As development continues on orismilast, which UNION therapeutics A/S believes will prove superior to Amgen, Inc.'s psoriasis drug Otezla, the Danish company has inked a potentially lucrative licensing deal with China's Innovent Biologics, Inc. for the next-generation PDE4 inhibitor.
Privately-held Union will bank $20m upfront and be entitled to receive additional milestone payments of up to $247m from Innovent...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?